BLASUBCUTANEOUSSOLUTION
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOGROYA (somapacitan-beco) is a long-acting human growth hormone (GH) analog administered subcutaneously, developed by Novo Nordisk and approved in 2020. It treats growth hormone deficiency, short stature, Turner syndrome, Noonan syndrome, and type 2 diabetes mellitus by providing sustained GH replacement over extended dosing intervals. The once-weekly subcutaneous formulation improves patient adherence compared to daily GH injections.
$0.163BPart D
PeakSOGROYA is in peak commercial phase with modest Medicare spending, suggesting a niche endocrine product with limited team expansion potential compared to mega-blockbusters.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
Started Oct 2023
200 enrolled
Growth Hormone Deficiency in Children
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Started Feb 2023
400 enrolled
Adult Growth Hormone Deficiency
Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®
Started Feb 2022
200 enrolled
Adult Growth Hormone Deficiency
Career Relevance
SOGROYA generates minimal linked job postings, reflecting its niche market position within Novo Nordisk's larger endocrinology portfolio. Career prospects are limited to boutique medical affairs and small regional sales teams rather than enterprise-wide brand infrastructure.
Worked on SOGROYA at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.